Concepedia

Richard McFetridge

RM

Statistics

Publications

15

Citations

789

H-Index

14

Active since

2010

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

The University of Western Australia

Ben-Gurion University of the Negev

Mahidol University

The University of Texas Medical Branch at Galveston

Richard McFetridge is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in vaccine safety, vaccinology, and vaccination.

Publications per year

2010–2023

15

Publications

15

Safety and Antibody Response, Including Antibody Persistence for 5 Years, after Primary Vaccination or Revaccination with Pneumococcal Polysaccharide Vaccine in Middle‐Aged and Older Adults

Daniel M. Musher, Susan B. Manoff, Charlie Liss et al. · The Journal of Infectious Diseases · 2010 · 159 citations · Full text

, , +17

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants

David Greenberg, Patricia Hoover, Timo Vesikari et al. · Vaccine · 2018 · 107 citations

, , +14

Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults

Daniel M. Musher, Susan B. Manoff, Richard McFetridge et al. · Human Vaccines · 2011 · 80 citations

, , +16

Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults

Richard McFetridge, Ajoke Sobanjo-ter Meulen, Steven Folkerth et al. · Vaccine · 2015 · 65 citations

, , +14

A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants

Heather Platt, David Greenberg, Bruce Tapiéro et al. · The Pediatric Infectious Disease Journal · 2020 · 64 citations · Full text

, , +17

1–5 of 15